BNTX - U.K. allergic reactions shouldn't interfere with FDA vaccine approval

The two anaphylactic allergic reactions reported by U.K. healthcare workers vaccinated against COVID-19 will likely be scrutinized by the FDA as it decides today whether to authorize Pfizer (PFE) and BioNTech's (BNTX) vaccine in the U.S., though the incident shouldn't hold up an approval.It's the sort of issue that the committee "deals with routinely because lots of vaccines are associated with allergic reactions in some small percentage of the population," said Dr. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center. People with underlying health conditions aren't commonly included in clinical trials.The COVID-19 vaccines are "more reactogenic than the flu vaccine," added Arnold Monto, an epidemiologist at the University of Michigan who leads the panel of experts that will advise the FDA about authorizing COVID vaccines. People shouldn't be caught by surprise or dissuaded from getting the two jabs, which come spaced three or four weeks apart.Both

For further details see:

U.K. allergic reactions shouldn't interfere with FDA vaccine approval